Patents Assigned to Bristol-Myers Squibb
  • Assay for Assessing Heart Failure
    Publication number: 20220317133
    Abstract: A method of immunoassay for detecting and/or monitoring a cardiovascular disease in a patient and/or assessing the likelihood of or the severity of a cardiovascular disease in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the ?3 chain of type VI collagen, and/or contacting a biofluid sample from the patient with a monoclonal antibody that specifically binds to a C-terminal neo-epitope of the N-terminal propeptide of type III collagen.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 6, 2022
    Applicants: Nordic Bioscience A/S, Bristol-Myers Squibb Company, The Trustees of the University of Pennsylvania
    Inventors: Federica Genovese, Morten Karsdal, Lei Zhao, David Gordon, Zhaoqing Wang, Julio Alonso Chirinos Medina
  • ANTI-PD-1 ANTIBODY FOR USE IN A METHOD OF TREATING A TUMOR
    Publication number: 20220315657
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.
    Type: Application
    Filed: March 21, 2022
    Publication date: October 6, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robin EDWARDS, Han CHANG, Michele CLEARY, Peter M. SZABO, Joseph Daniel SZUSTAKOWSKI, Patrik VITAZKA
  • ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20220298243
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Application
    Filed: April 7, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • PSGL-1 Antagonists and Uses Thereof
    Publication number: 20220298258
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Application
    Filed: March 15, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • Substituted indole compounds useful as inhibitors of TLR7/8/9
    Patent number: 11447466
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: Y is Formula (II), or Formula (III); R1, R2, R2a, R2b, R2c, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Brian K. Whiteley, John L. Gilmore
  • Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
    Patent number: 11447475
    Abstract: The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Yan Shi, Robert F. Kaltenbach, III, Ying Wang, Hao Zhang
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11447775
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 20, 2022
    Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Spiroheptanyl hydantoins as rock inhibitors
    Patent number: 11447487
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Fibronectin based scaffold proteins
    Patent number: 11447538
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 20, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dasa Lipovsek, Jonathan H. Davis
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11447449
    Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, David K. Williams, Murugaiah Andappan Murugaiah Subbaiah
  • Aminoimidazopyridazines as kinase inhibitors
    Patent number: 11440913
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
  • TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY
    Publication number: 20220281974
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 8, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF
    Publication number: 20220281980
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Application
    Filed: January 24, 2022
    Publication date: September 8, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michelle Renee KUHNE, Alan J. KORMAN, Haichun HUANG, Yiming YIN, Robert F. GRAZIANO, Natalie A. BEZMAN, Pavel STROP, Richard Y. HUANG, Guodong CHEN, Mohan SRINIVASAN, Peter Sung Keun LEE, Gamze Ozlem CAMDERE
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 11434275
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: September 6, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
    Publication number: 20220275535
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Application
    Filed: February 16, 2022
    Publication date: September 1, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jonathan DAVIS, Dasa LIPOVSEK, Ray CAMPHAUSEN
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11427610
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 30, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Yufen Zhao, Libing Chen, Audris Huang
  • 6-azaindole compounds
    Patent number: 11427580
    Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 30, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
  • Aryl and heteroaryl substituted indole compounds
    Patent number: 11420958
    Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 23, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Christopher P. Mussari, Tasir Shamsul Haque, Brian K. Whiteley, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy, Rushith Kumar Anumula
  • Method to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids
    Patent number: 11421278
    Abstract: The present invention relates generally to a method of monitoring pharmacodynamic responses mediated by in vivo administration of glucocorticoids. More specifically, the present invention relates to a method of using a change in gene signature as a pharmacodynamic marker of glucocorticoid exposure.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 23, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Julie Carman, Yanhua Hu
  • Amide substituted indole compounds useful as TLR inhibitors
    Patent number: 11420973
    Abstract: N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 23, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Tasir Shamsul Haque, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Rushith Kumar Anumula